Format

Send to

Choose Destination
J Autism Dev Disord. 2011 Feb;41(2):175-84. doi: 10.1007/s10803-010-1036-5.

Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

Author information

1
Lime Trees Child, Adolescent and Family Unit, 31 Shipton Road, York, North Yorkshire, YO30 5RE, England, UK. barry.wright@nyypct.nhs.uk

Abstract

Twenty-two children with autism spectrum disorders who had not responded to supported behaviour management strategies for severe dysomnias entered a double blind, randomised, controlled crossover trial involving 3 months of placebo versus 3 months of melatonin to a maximum dose of 10 mg. 17 children completed the study. There were no significant differences between sleep variables at baseline. Melatonin significantly improved sleep latency (by an average of 47 min) and total sleep (by an average of 52 min) compared to placebo, but not number of night wakenings. The side effect profile was low and not significantly different between the two arms.

PMID:
20535539
DOI:
10.1007/s10803-010-1036-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center